术前血小板和淋巴细胞比值对胃间质瘤患者预后的预测价值
DOI: 10.3971/j.issn.1000-8578.2018.17.1428
Keywords: A Meta-analysis,Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression,Advances in Prognostic Value of Peripheral Blood Inflammatory Indexes in Non-small Cell Lung Cancer,Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castrationresistant Prostate Cancer Patients,Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer,Predictive Value of Preoperative Hematologic Inflammatory Markers in Prognostic of Glioma Patients,Clinical Treatment and Prognosis of 101 Patients with Small Cell Neuroendocrine Carcinoma of Cervix,Effect of Marital Status on Survival of Lung Cancer Patients Investigated Based on SEER Database,Clinical Characteristics and Prognosis of Primary Thyroid Lymphoma Patients,Prognostic Factors and Comprehensive Treatment of 95 Synovial Sarcoma Patients,Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
Abstract:
摘要 目的 探讨术前血小板/淋巴细胞比值(PLR)在胃间质瘤(GST)患者预后评估中的作用。方法 回顾性分析了92例GST患者的临床病例资料。收集所有GST患者术前3天血常规PLR数值及其病理切片中免疫组织化学检测结果。根据术前外周血PLR分为低PLR组(PLR<130, 38例)和高PLR组(PLR≥130, 54例),比较两组GST患者的生存情况,分析临床病理因素与术后无瘤生存率、总生存率之间的关系。结果 术前PLR与GST临床病理特征中的核分裂相有关(χ2=5.95, P=0.015)。术前高PLR组患者的无瘤生存率明显低于术前低PLR组,差异有统计学意义(χ2=6.17, P=0.018)。单因素分析结果显示,术前PLR、术后是否接受伊马替尼治疗、美国国立卫生研究院(NIH)的肿瘤恶性潜能分级、肿瘤大小、肿瘤核分裂相与GST的术后无瘤生存率相关(P<0.05)。多因素分析结果发现,术前PLR是GST术后无瘤生存率的独立预后因素(P<0.05)。结论 术前PLR可作为GST的独立预后因素。术前高PLR可能提示GST患者预后不良
Full-Text